Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction
Status:
Terminated
Trial end date:
2015-12-16
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of dabrafenib in treating patients
with solid tumors and kidney or liver dysfunction. Dabrafenib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth.